WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 522540
CAS#: 245063-59-6
Description: NS-1209 is an antiepileptic drug candidate currently under clinical trials. Epilepsy is one of the most common serious neurological disorders in adults, affecting approximately 50 million people worldwide at a total annual cost, in Europe, of approximately 15.5 billion Euros.
MedKoo Cat#: 522540
Name: NS-1209
CAS#: 245063-59-6
Chemical Formula: C24H28N4O7S
Exact Mass: 516.1679
Molecular Weight: 516.57
Elemental Analysis: C, 55.80; H, 5.46; N, 10.85; O, 21.68; S, 6.21
NS-1209 is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.
Synonym: NS-1209; NS 1209; NS1209; 245063-59-6; SPD-502; SPD502; SPD 502
IUPAC/Chemical Name: (R,Z)-2-(((5-(4-(N,N-dimethylsulfamoyl)phenyl)-8-methyl-2-oxo-1,2,6,7,8,9-hexahydro-3H-pyrrolo[3,2-h]isoquinolin-3-ylidene)amino)oxy)-4-hydroxybutanoic acid
InChi Key: CFJRSKULEDUDKL-HXUWFJFHSA-N
InChi Code: InChI=1S/C24H28N4O7S/c1-27(2)36(33,34)15-6-4-14(5-7-15)17-12-18-21(19-13-28(3)10-8-16(17)19)25-23(30)22(18)26-35-20(9-11-29)24(31)32/h4-7,12,20,29H,8-11,13H2,1-3H3,(H,31,32)(H,25,26,30)/t20-/m1/s1
SMILES Code: O=C(O)[C@H](O/N=C1C2=C(C(C3)=C(CCN3C)C(C4=CC=C(C=C4)S(N(C)C)(=O)=O)=C2)NC/1=O)CCO
The following data is based on the product molecular weight 516.57 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Mula M. Emerging drugs for focal epilepsy. Expert Opin Emerg Drugs. 2013 Mar;18(1):87-95. doi: 10.1517/14728214.2013.750294. Epub 2012 Nov 26. Review. PubMed PMID: 23176519.
2: Perucca E. What is the promise of new antiepileptic drugs in status epilepticus? Focus on brivaracetam, carisbamate, lacosamide, NS-1209, and topiramate. Epilepsia. 2009 Dec;50 Suppl 12:49-50. doi: 10.1111/j.1528-1167.2009.02366.x. Review. PubMed PMID: 19941524.
3: Landmark CJ, Johannessen SI. Modifications of antiepileptic drugs for improved tolerability and efficacy. Perspect Medicin Chem. 2008 Feb 14;2:21-39. PubMed PMID: 19787095; PubMed Central PMCID: PMC2746576.
4: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2004 Mar;26(2):129-61. PubMed PMID: 15071612.